#news #biotech Kadmon clinical POC data raise expectations for IPF drug

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Kadmon clinical POC data raise expectations for IPF drug .Kadmon has posted clinical proof-of-concept data on its idiopathic pulmonary fibrosis (IPF) candidate KD025. The ROCK2 inhibitor had a stronger effect on forced vital capacity than standard of care, but the small, open-label nature of the study and lack of detail in the top-line data leave scope for doubts about its efficacy.

from FierceBiotech: Biotech http://ift.tt/2F2dBkk